Back to News
Market Impact: 0.2
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
X4 Pharmaceuticals expects to complete enrollment in the pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia by the end of Q4 2026. The company anticipates top-line data in Q1 2028.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
XFOR0.10
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- PC chip plunge wipes out a quarter of Intel’s value
- Intel plunges on a major guidance miss. What went wrong — and how to proceed
- FedEx Freight delivers a much-needed quarterly beat. Where we stand on shares now